110 related articles for article (PubMed ID: 11147134)
1. High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach.
Taneja D; Namdeo A; Mishra PR; Khopade AJ; Jain NK
Drug Dev Ind Pharm; 2000 Dec; 26(12):1315-9. PubMed ID: 11147134
[TBL] [Abstract][Full Text] [Related]
2. 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity.
Umrethia M; Ghosh PK; Majithya R; Murthy RS
Cancer Invest; 2007 Mar; 25(2):117-23. PubMed ID: 17453823
[TBL] [Abstract][Full Text] [Related]
3. Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia.
Qiu J; Cheng R; Zhang J; Sun H; Deng C; Meng F; Zhong Z
Biomacromolecules; 2017 Oct; 18(10):3207-3214. PubMed ID: 28835099
[TBL] [Abstract][Full Text] [Related]
4. Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma.
Alekseeva AA; Moiseeva EV; Onishchenko NR; Boldyrev IA; Singin AS; Budko AP; Shprakh ZS; Molotkovsky JG; Vodovozova EL
Int J Nanomedicine; 2017; 12():3735-3749. PubMed ID: 28553111
[TBL] [Abstract][Full Text] [Related]
5. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
7. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats.
Allen TM; Everest JM
J Pharmacol Exp Ther; 1983 Aug; 226(2):539-44. PubMed ID: 6875864
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
9. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
10. Study of azathioprine encapsulation into liposomes.
Gulati M; Grover M; Singh M; Singh S
J Microencapsul; 1998; 15(4):485-94. PubMed ID: 9651870
[TBL] [Abstract][Full Text] [Related]
11. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
12. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
13. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: S6-acyloxymethyl-6-mercaptopurine prodrugs.
Waranis RP; Sloan KB
J Pharm Sci; 1988 Mar; 77(3):210-5. PubMed ID: 3373424
[TBL] [Abstract][Full Text] [Related]
14. Characterization of drug release from liposomal formulations in ocular fluid.
Jafari MR; Jones AB; Hikal AH; Williamson JS; Wyandt CM
Drug Deliv; 1998; 5(4):227-38. PubMed ID: 19569989
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacogenetics to optimization of mercaptopurine dosing.
Balis FM; Adamson PC
J Natl Cancer Inst; 1999 Dec; 91(23):1983-5. PubMed ID: 10580012
[No Abstract] [Full Text] [Related]
16. 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization.
Agrawal V; Paul MK; Mukhopadhyay AK
J Liposome Res; 2005; 15(3-4):141-55. PubMed ID: 16393906
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
[TBL] [Abstract][Full Text] [Related]
18. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
[TBL] [Abstract][Full Text] [Related]
20. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
